Medications for neurodegenerative diseases

Last updated: November 01, 2022

Medications for neurodegenerative diseases

BMB2

BMB2

Seizures: Pathology review
Seizures: Clinical
Febrile seizure
Seizures and epilepsy
Early infantile epileptic encephalopathy (NORD)
Nonbenzodiazepine anticonvulsants
Migraine medications
Migraine
Neuron action potential
Resting membrane potential
Concussion and traumatic brain injury
Sleep
Sleep disorders: Clinical
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Essential tremor
Malingering, factitious disorders and somatoform disorders: Pathology review
Somatic symptom disorders: Clinical
Somatic symptom disorder
Dissociative disorders
Dissociative disorders: Clinical
Amnesia, dissociative disorders and delirium: Pathology review
Narcolepsy (NORD)
Psychomotor stimulants
Trigeminal neuralgia
Muscle weakness: Clinical
Myalgias and myositis: Pathology review
Fibromyalgia
Diabetic nephropathy
Tricyclic antidepressants
Atypical antidepressants
Medications for neurodegenerative diseases
Toxidromes: Clinical
Body focused repetitive disorders
Headaches: Clinical
Demyelinating disorders: Pathology review
Serotonin and norepinephrine reuptake inhibitors
Erb-Duchenne palsy
Klumpke paralysis
Lead poisoning
Hemolytic-uremic syndrome
Vitamin B12 deficiency
Monoclonal gammopathy of undetermined significance
Charcot-Marie-Tooth disease
Inflammatory myopathies: Clinical
Guillain-Barre syndrome
Amyotrophic lateral sclerosis
Spinal muscular atrophy
Muscular dystrophy
Spinal cord reflexes
Myotonic dystrophy
Memory palaces
Herpes simplex virus
Neuromuscular junction and motor unit
Slow twitch and fast twitch muscle fibers
Muscle contraction
Development of the muscular system
Development of the axial skeleton
Patellar tendon rupture
Achilles tendon rupture
Lower back pain: Clinical
Carpal tunnel syndrome
Radial head subluxation (Nursemaid elbow)
Bell palsy
Headaches: Pathology review
Cluster headache
Tension headache
Epidural hematoma
Traumatic brain injury: Clinical
Intracerebral hemorrhage
Subarachnoid hemorrhage
Subdural hematoma
Traumatic brain injury: Pathology review
Idiopathic intracranial hypertension
Vasculitis
Vasculitis: Clinical
Dementia with Lewy bodies
Spinocerebellar ataxia (NORD)
Amyloidosis
Vascular dementia
Dementia and delirium: Clinical
Frontotemporal dementia
Dementia: Pathology review
Hypokinetic movement disorders: Clinical
Alzheimer disease
Movement disorders: Pathology review
Delirium
Parkinson disease
Hyperkinetic movement disorders: Clinical
Back pain: Pathology review
Stroke: Clinical
Compartment syndrome
Macrocytic anemia: Pathology review
Hypokalemia: Clinical
Hyperkalemia: Clinical
Hypothesis testing: One-tailed and two-tailed tests
Paired t-test
One-way ANOVA
Two-way ANOVA
Type I and type II errors
Two-sample t-test
Correlation
Repeated measures ANOVA
Meningitis, encephalitis and brain abscesses: Clinical
Neonatal meningitis
Central nervous system infections: Pathology review
Neisseria meningitidis
Streptococcus pneumoniae
Listeria monocytogenes
Brain abscess
Clostridium tetani (Tetanus)
Clostridium botulinum (Botulism)
Encephalitis
Eastern and Western equine encephalitis virus
West Nile virus
Zika virus
Rabies virus
Poliovirus
JC virus (Progressive multifocal leukoencephalopathy)
Knowledge Shot: What is acute flaccid myelitis, the polio-like paralyzing disease
Meningitis
Cryptococcus neoformans
Aspergillus fumigatus
Candida
Mucormycosis
Coccidioidomycosis and paracoccidioidomycosis
Blastomycosis
Histoplasmosis
Chi-squared test
Naegleria fowleri (Primary amebic meningoencephalitis)
Angiostrongylus (Eosinophilic meningitis)
Varicella zoster virus
Mycobacterium tuberculosis (Tuberculosis)
Normal pressure hydrocephalus
Prions (Spongiform encephalopathy)
Measles virus
Central nervous system infections: Pathology review
Meningitis, encephalitis and brain abscesses: Clinical
Adult brain tumors
Pediatric brain tumors: Pathology review
Adult brain tumors: Pathology review
Pediatric brain tumors
Brain tumors: Clinical
Multiple sclerosis
Tourette syndrome
Ataxia-telangiectasia
Huntington disease
Opsoclonus myoclonus syndrome (NORD)
Primary ciliary dyskinesia
Brain herniation
Spinal disc herniation
Multiple myeloma

Transcript

Watch video only

Huntington disease, or HD, is a rare neurodegenerative disease that involves a repeated sequence of DNA that causes an abnormal protein to form, leading to abnormal movements and cognitive problems.

In most people, a gene called huntingtin or HTT on chromosome 4, contains a triplet repeat, where the nucleotides C, A, and G are repeated 10-35 times in a row. In people with Huntington disease, this repeat goes on for 36 or more times in a row.

CAG codes for the amino acid glutamine, so people with Huntington disease will have 36 or more glutamines in a row in the huntingtin protein.

So, in addition to being a triplet repeat disorder, HD is, more specifically, a “polyglutamine” disease.

The specific way in which extra glutamines causes HD symptoms isn’t fully worked out, but some clues are that the mutated protein aggregates within the neuronal cells of the caudate and putamen of the basal ganglia causing neuronal cell death.

Cell death might be related to excitotoxicity, which is excessive signaling of these neurons, which leads to high intracellular calcium.

Now the symptoms of HD involve progressive CNS disturbances including movement, cognitive, and mood symptoms and they start appearing around the age of 40.

Remember, the age of onset depends on the number of CAG repeats, so more repeats means earlier onset.

Over time, if enough of the neurons die in the caudate and putamen, which together form the dorsal striatum, then it can cause actual loss of brain tissue volume in that area and expansion of the lateral ventricles.

The death of neurons also cause neurotransmitter imbalance in these regions and there’s a decrease in inhibitory neurotransmitters like GABA, and an increase in stimulatory neurons like dopamine.

This also decreases acetylcholine, which is released by interneurons that help other neurons communicate.

Now, the affected areas play an important role in movement, particularly inhibiting it, so cell death in the basal ganglia causes movement problems like chorea, which are purposeless, dance-like jerking movements, and athetosis which are slower, writhing, “snake-like” movements mainly affecting the hands.

These involuntary movements can’t be consciously suppressed and stop only with sleep.

Other motor problems include abnormal eye movements and poor coordination.

Loss of tissue in these regions can also lead to psychological problems as well.

These people often experience psychosis and agitation, leading to disruptive behavior, and mood disorders like major depressive disorder.

They might also develop dementia and severe cognitive defects.

Since the muscles for swallowing become discoordinated, these people often suffer from dysphagia and aspiration pneumonia.

Unfortunately, there is no treatment to stop or reverse Huntington disease, and death usually happens within 10-20 years of diagnosis, often by aspiration pneumonia or suicide.

The medications used for Huntington disease are focused around managing the symptoms like chorea, and psychosis.

Since dopamine is increased in the regions of the brain affected, medications that lower dopamine levels or act as antagonists are usually used. These include tetrabenazine, and antipsychotics.

Let’s start with tetrabenazine and its deuterated form, deutetrabenazine.

Deuterated simply means some of the hydrogen molecules in the medication have been replaced by the more stable deuterium isotope to improve the half life of the drug.

These medications work on both presynaptic and postsynaptic neurons.

In the presynaptic neuron, they block vesicular monoamine transporters, or VMAT found on the vesicles.

These transport proteins allow dopamine into the vesicles for storage, so when they are inhibited, the vesicles can’t release dopamine into the synaptic cleft.

Next, on the postsynaptic neuron, these medications act as a weak dopamine receptor antagonist, so they bind to the receptors and prevent dopamine from binding.

Tetrabenazine and deutetrabenazine are often used for the treatment of chorea in Huntington disease. However, they are also useful for treating Tourette’s syndrome, which is a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics.

Key Takeaways

There are a few different types of medications that can be prescribed for neurodegenerative diseases. One common type is called cholinesterase inhibitors, which work by preventing the breakdown of the neurotransmitter acetylcholine. This type of medication can help to improve cognitive function and memory in people with Alzheimer's disease.

Another common type of medication for neurodegenerative diseases is NMDA receptor blockers. This type of medication helps to prevent damage to nerve cells by blocking the action of glutamate, a chemical that can be harmful to nerve cells. Blocking glutamate can help to preserve nerve function and reduce symptoms in people with conditions such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Deuterium Tetrabenazine for Tardive Dyskinesia" Clin Schizophr Relat Psychoses (2018)
  5. "Huntington's Disease-Update on Treatments" Curr Neurol Neurosci Rep (2017)
  6. "Antipsychotic drugs in Huntington's disease" Expert Rev Neurother (2017)